Corrigendum to “Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables” [Int. J. Mycobacteriol. 5(1) 2016 1-6]. Go to Publication You Might Also Like Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay. March 2, 2015 LABAs and asthma: from the SMART study to the SMART approach. December 15, 2010 BCG and New Preventive Tuberculosis Vaccines: Implications for Healthcare Workers. May 3, 2016 A 12-year-old girl with Hodgkin’s disease presenting as a non-resolving pneumonia and an endobronchial nodule. November 15, 2009 Dual infection with HIV-1 and HIV-2. June 30, 1997
Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay. March 2, 2015
A 12-year-old girl with Hodgkin’s disease presenting as a non-resolving pneumonia and an endobronchial nodule. November 15, 2009